PDF herunterladen
CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(03): 140-144
DOI: 10.4103/sajc.sajc_300_18
ORIGINAL ARTICLE: Breast Cancers

Correlation of digital mammography and digital breast tomosynthesis features of self-detected breast cancers with human epidermal growth factor receptor type 2/neu status

Chaitra Sonthineni
Department of Endocrine and Breast Surgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh
,
Namita Mohindra
Department of Radio-Diagnosis, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh
,
Vinita Agrawal
Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh
,
Zafar Neyaz
Department of Radio-Diagnosis, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh
,
Neeraj Jain
Department of Radio-Diagnosis, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh
,
Sabaretnam Mayilvagnan
Department of Endocrine and Breast Surgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh
,
Gaurav Agarwal
Department of Endocrine and Breast Surgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh
› Institutsangaben Financial support and sponsorship Nil.
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints

Abstract

Context: Breast cancer is a heterogeneous disease with several histological subtypes. Its prognosis and management are influenced by human epidermal growth factor receptor type 2 (HER2/neu) expression. Varying grades of HER2/neu overexpression are likely to have different morphological features. Digital breast tomosynthesis (DBT) enhances lesion visibility and hence that it may reveal features closer to histomorphological findings. Aims: The aim of this study is to correlate digital mammography (DM) and DBT findings of self-detected tumors with HER2/neu status, to determine whether differences in imaging features can help predict the degrees of HER2/neu overexpression. Settings and Design: Prospective study conducted in a tertiary care hospital. Methods: For 100 consecutive patients with self-detected lumps, DM and DBT data were reviewed by two radiologists who were blinded to histopathology. Of these, 63 patients with histologically proven breast cancer were recruited and their DM and DBT findings compared and correlated with HER2neu status (scores 0–3+). Statistical Analysis: Pearson's Chi-squared test and Fisher's exact test were used (SPSS version 22.0, IBM). Results: Morphology of lesions at both DM and DBT varied with HER2/neu status (P = 0.04 and 0.015, respectively). HER2-0 tumors mostly presented as masses without microcalcifications (88.8%), while most of HER2-3+ tumors as masses or asymmetries with microcalcifications (61.9%). The presence or absence of calcifications varied significantly with HER2/neu status. Breast imaging-reporting and data system (BI-RADS) scoring varied significantly (P < 0.001) with higher HER2 signal, more frequently associated with BI-RADS 5 score. Conclusion: DM and DBT features vary with the intensity of HER2 immunostaining. Higher BI-RADS scores, microcalcifications, and spiculated margins are frequently associated with HER2/neu 3+ lesions.

Key words

Breast carcinoma - digital breast tomosynthesis - digital mammography - human epidermal growth factor receptor type 2/neu - immunohistochemistry


Publikationsverlauf

Artikel online veröffentlicht:
21. Dezember 2020

© 2019. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010 Oct;34(10):2308-24. doi: 10.1007/s00268-010-0683-1. PubMed PMID: 20607258; PubMed Central PMCID: PMC2936680.
  • 2 Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F. HER2/neu role in breast cancer: From a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 2007;19:56-62.
  • 3 Kumar V, Tewari M, Singh U, Shukla HS. Significance of Her-2/neu protein over expression in Indian breast cancer patients. Indian J Surg 2007;69:122-8.
  • 4 Zhou BP, Hung MC. Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol 2003;30:38-48.
  • 5 Elias SG, Adams A, Wisner DJ, Esserman LJ, Van't Veer LJ, Mali WP, et al. Imaging features of HER2 overexpression in breast cancer: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014;23:1464-83.
  • 6 Roth RG, Maidment AD, Weinstein SP, Roth SO, Conant EF. Digital breast tomosynthesis: Lessons learned from early clinical implementation. Radiographics 2014;34:E89-102.
  • 7 Houssami N, Skaane P. Overview of the evidence on digital breast tomosynthesis in breast cancer detection. Breast 2013;22:101-8.
  • 8 Sickles EA, D'Orsi CJ, Bassett LW, Appleton CM, Berg WA, Burnside ES, et al. ACR BIRADS® mammography. In: ACR BIRADS® Atlas, Breast Imaging Reporting and Data System. Reston, VA: American College of Radiology; 2013.
  • 9 Lång K, Andersson I, Zackrisson S. Breast cancer detection in digital breast tomosynthesis and digital mammography-a side-by-side review of discrepant cases. Br J Radiol 2014;87:20140080.
  • 10 Poplack SP, Tosteson TD, Kogel CA, Nagy HM. Digital breast tomosynthesis: Initial experience in 98 women with abnormal digital screening mammography. AJR Am J Roentgenol 2007;189:616-23.
  • 11 Gilbert FJ, Tucker L, Gillan MG, Willsher P, Cooke J, Duncan KA, et al. The TOMMY trial: A comparison of TOMosynthesis with digital MammographY in the UK NHS breast screening programme – A multicentre retrospective reading study comparing the diagnostic performance of digital breast tomosynthesis and digital mammography with digital mammography alone. Health Technol Assess 2015;19:i-xxv, 1-136.
  • 12 Gao B, Zhang H, Zhang SD, Cheng XY, Zheng SM, Sun YH, et al. Mammographic and clinicopathological features of triple-negative breast cancer. Br J Radiol 2014;87:20130496.
  • 13 Krizmanich-Conniff KM, Paramagul C, Patterson SK, Helvie MA, Roubidoux MA, Myles JD, et al. Triple receptor-negative breast cancer: Imaging and clinical characteristics. AJR Am J Roentgenol 2012;199:458-64.
  • 14 Farrokh D, Boloursaz S, Homai F. Relationship among mammographic findings with histopathologic type of breast cancer and human epidermal growth factor receptor 2 (HER2) in young women. Electron Physician 2017;25;9:4300-5.
  • 15 Wang X, Chao L, Chen L, Tian B, Zang Y, Hua M, et al. Correlation of mammographic calcifications with HER2/NEU over expression in primary breast carcinomas. J Digit Imaging 2008;21;170-6.
  • 16 Sun SS, Zhang B, Zhao HM, Cao XC. Association between mammographic features and clinicopathological characteristics in invasive ductal carcinoma of breast cancer. Mol Clin Oncol 2014;2:623-9.
  • 17 Bae MS, Moon WK, Chang JM, Cho N, Park SY, Won JK, et al. Mammographic features of calcifications in DCIS: Correlation with oestrogen receptor and human epidermal growth factor receptor 2 status. Eur Radiol 2013;23:2072-8.